Aberrant trophoblastic differentiation in human cancer: An emerging novel therapeutic target (Review)

Chen Chang, Yi Lin Chen, Yi-Wen Wang, Hui Wen Chen, Che Wei Hsu, Kun Che Lin, Ying-Chien Ou, Tsunglin Liu, Wan Li Chen, Chien An Chu, Chung Liang Ho, Chung Ta Lee, Nan Haw Chow

研究成果: Review article同行評審


Various types of human cancer may develop aberrant trophoblastic differentiation, including histological changes and altered expression of β‑human chorionic gonado‑ tropin (β‑hCG). Aberrant trophoblastic differentiation in epithelial cancer is usually associated with poor differentia‑ tion, tumor metastasis, unfavorable prognosis and treatment resistance. Since β‑hCG‑targeting vaccines have failed in an early phase II trial, it is crucial to obtain a better understanding of the molecular pathogenesis of trophoblastic differentiation in human cancer. The present review summarizes the clinical and translational research on this topic with the aim of acceler‑ ating the development of an effective targeted therapy. Ectopic expression of β‑hCG promotes proliferation, migration, inva‑ sion, vasculogenesis and epithelial‑mesenchymal transition (EMT) in vitro, and enhances metastatic and tumorigenic capabilities in vivo. Signaling cascades modulated by β‑hCG include the TGF‑β receptor pathway, EMT‑related pathways, the c‑MET receptor tyrosine kinase and mitogen‑activated protein kinase/ERK pathways, and the SMAD2/4 pathway. Taken together, these findings indicated that TGF‑β recep‑ tors, c‑MET and ERK1/2 are potential therapeutic targets. Nevertheless, further investigation on the molecular basis of aberrant trophoblastic differentiation is mandatory to improve the design of precision therapy for this aggressive type of human cancer.

期刊Oncology Reports
出版狀態Published - 2024 3月

All Science Journal Classification (ASJC) codes

  • 腫瘤科
  • 癌症研究


深入研究「Aberrant trophoblastic differentiation in human cancer: An emerging novel therapeutic target (Review)」主題。共同形成了獨特的指紋。